Organon (OGN) Depreciation & Amortization (CF) (2020 - 2026)

Organon (OGN) recorded quarterly Depreciation & Amortization (CF) of $39.0 million in Q1 2026, down 15.22% quarter-over-quarter from $46.0 million in Q4 2025, and up 14.71% on a YoY basis from $34.0 million in Q1 2025.

Organon (OGN) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends

Organon's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $39.0 million for Q1 2026.

  • In Q1 2026, Depreciation & Amortization (CF) rose 14.71% year-over-year to $39.0 million; the TTM figure through Mar 2026 stood at $161.0 million (up 20.15% YoY), while the FY2025 annual figure was $156.0 million, up 18.18% from the prior year.
  • Depreciation & Amortization (CF) was $39.0 million for Q1 2026 at Organon, down from $46.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $46.0 million in Q4 2025 to a low of $22.0 million in Q2 2022.
  • Historically, Depreciation & Amortization (CF) has averaged $31.9 million across 5 years, with a median of $32.0 million in 2023.
  • Biggest YoY gain for Depreciation & Amortization (CF) was 38.89% in 2022; the steepest drop was 14.29% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $24.0 million in 2022, then surged by 33.33% to $32.0 million in 2023, then climbed by 6.25% to $34.0 million in 2024, then jumped by 35.29% to $46.0 million in 2025, then dropped by 15.22% to $39.0 million in 2026.
  • The last three Depreciation & Amortization (CF) figures came in at $39.0 million (Q1 2026), $46.0 million (Q4 2025), and $40.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Gsk 93,026,132.38 Bn 93,026,127.42 Bn 7.76 Bn -
2 Eli Lilly 1,022.62 Bn 1,017.34 Bn 16.22 Bn 509.00 Mn
3 Johnson & Johnson 570.65 Bn 548.59 Bn 15.96 Bn 2.00 Bn
4 AbbVie 398.73 Bn 389.38 Bn 10.78 Bn 188.00 Mn
5 Merck 295.53 Bn 289.88 Bn 12.09 Bn 581.00 Mn
6 Amgen 186.30 Bn 174.26 Bn 5.87 Bn 1.12 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn 93.00 Mn
8 Pfizer 146.09 Bn 133.32 Bn -1.21 Bn 1.61 Bn
9 Bristol Myers Squibb 114.98 Bn 104.53 Bn 8.07 Bn 594.00 Mn
10 Organon 3.49 Bn 2.37 Bn 783.00 Mn 39.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 39.00 Mn
Mar 31, 2026 39.00 Mn
Dec 31, 2025 46.00 Mn
Dec 31, 2025 46.00 Mn
Sep 30, 2025 40.00 Mn
Sep 30, 2025 40.00 Mn
Jun 30, 2025 36.00 Mn
Jun 30, 2025 36.00 Mn
Mar 31, 2025 34.00 Mn
Mar 31, 2025 34.00 Mn
Dec 31, 2024 34.00 Mn
Dec 31, 2024 34.00 Mn
Sep 30, 2024 34.00 Mn
Sep 30, 2024 34.00 Mn
Jun 30, 2024 32.00 Mn
Jun 30, 2024 32.00 Mn
Mar 31, 2024 32.00 Mn
Mar 31, 2024 32.00 Mn
Dec 31, 2023 32.00 Mn
Dec 31, 2023 32.00 Mn